Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Investing.com -- Citi downgraded both AbbVie (NYSE: ABBV) and Merck (NSE: PROR) to Neutral in separate notes Wednesday, ...

Alistair Barr formerly covered Google for The Wall Street Journal. Alistair has covered technology and finance for roughly two decades at the WSJ, USA Today, Reuters, MarketWatch and Bloomberg. Google ...

Oral ivarmacitinib was effective for the treatment of moderate to severe atopic dermatitis in adults and adolescents, ...

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

China's Huawei will launch its first laptop with the self-developed Harmony operating system on May 19, the company said in a ...

Despite conclusive proof of Abbvie sponsoring foreign tours for 30 doctors, violating marketing practices, the National ...

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, announces the winners ...

AbbVie will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025. Management will participate in a fireside chat at 12:00 p.m. Central time. A live audio ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

AbbVie announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the ...